USP Launches Initiative to Fight Counterfeit Drugs in Sub-Saharan Africa - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

USP Launches Initiative to Fight Counterfeit Drugs in Sub-Saharan Africa


The United States Pharmacopeial Convention (USP) has announced the launch of the Center for Pharmaceutical Advancement and Training (CePAT) in Accra, Ghana. CePAT is part of USP’s initiative to combat drug counterfeiting in Sub-Saharan Africa. The center is also part of the organization’s effort to promote global access to good quality medicines and is being launched as a Commitment to Action through the Clinton Global Initiative (CGI).

“CePAT is a natural extension of USP’s core mission of establishing public standards for the quality of medicines, foods, and dietary supplements. As USP has become increasingly active throughout the world, the need to support efforts to provide good quality medicines to everyone who requires them has become more important. CePAT is a positive step in that direction, and has been realized in part through our strong working relationships with the Ghanaian and other Sub-Saharan African medicines regulatory authorities,” Roger L. Williams, MD, USP’s chief executive officer, stated in a USP press release.

Substandard and counterfeit medicines are a problem in Sub-Saharan Africa where more than 90% of drug samples tested by USAID-USP failed either the test for API or sterility, and only three of the 26 products tested were officially registered with the Ghana Food and Drug Authority.  US Ambassador to Ghana, Gene Allan Cretz, said in the press release, “Improvements in this area are critical, and I am proud that CePAT is playing a role in tackling this problem, and that the US Presidents’ Malaria Initiative and USAID activities laid the groundwork for establishing USP in Ghana.”

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
28%
Oversee medical treatment of patients in the US.
12%
Provide treatment for patients globally.
9%
All of the above.
45%
No government involvement in patient treatment or drug development.
7%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing

Click here